The FDA Just Rejected a Bid for MDMA’s Approval to Treat PTSD

Quick Summary:

The agency has asked drugmaker Lykos Therapeutics to run an additional study on the use of the psychedelic drug in patients with post-traumatic stress disorder, pushing back its next proposal by years.

The company said Friday that the regulatory agency has requested an additional Phase 3 trial so that the safety and efficacy of the therapy can be further studied.

One major question raised by the advisory committee was the extent to which the talk therapy contributes to the treatment benefit.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Emily Mullin

Category: TechnologyEconomy

Markets: United StatesOman

Topics: Science / Health Science

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-08-09 @ 22:50:32 (18 hours ago)

News Timezone: GMT +8:00

News Source URL: wired.com

Language: English

Article Length: 1039 words

Reading Time: 6 minutes read

Sentences: 46 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Wired

News ID: 22002256

View Article Analysis

About Wired

Main Topics: TechnologyEconomy

Official Website: wired.com

Update Frequency: 8 posts per day

Year Established: 1993

Headquarters: United States

News Last Updated: 9 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #111

Publisher Details

Frequently Asked Questions